Put Options

18 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2024

Apr 19, 2024

BUY
$7.59 - $17.47 $160,908 - $370,364
21,200 New
21,200 $6,000
Q3 2023

Nov 07, 2023

BUY
$4.44 - $8.79 $15,540 - $30,764
3,500 New
3,500 $10,000
Q3 2022

Oct 25, 2022

SELL
$9.53 - $13.11 $4,765 - $6,555
-500 Reduced 45.45%
600 $1,000
Q2 2022

Aug 04, 2022

SELL
$6.38 - $18.33 $150,568 - $432,587
-23,600 Reduced 95.55%
1,100 $2,000
Q1 2022

Apr 14, 2022

BUY
$12.38 - $19.1 $252,552 - $389,640
20,400 Added 474.42%
24,700 $13,000
Q4 2021

Jan 18, 2022

SELL
$16.55 - $27.63 $862,255 - $1.44 Million
-52,100 Reduced 92.38%
4,300 $12,000
Q3 2021

Oct 26, 2021

BUY
$20.35 - $26.63 $807,895 - $1.06 Million
39,700 Added 237.72%
56,400 $97,000
Q2 2021

Jul 19, 2021

BUY
$16.33 - $33.07 $262,913 - $532,427
16,100 Added 2683.33%
16,700 $18,000
Q1 2021

Apr 26, 2021

SELL
$28.67 - $52.59 $71,675 - $131,475
-2,500 Reduced 80.65%
600 $1,000
Q4 2020

Jan 21, 2021

BUY
$28.04 - $50.26 $56,080 - $100,520
2,000 Added 181.82%
3,100 $0
Q3 2020

Oct 27, 2020

SELL
$27.75 - $36.3 $130,425 - $170,610
-4,700 Reduced 81.03%
1,100 $4,000
Q2 2020

Jul 22, 2020

BUY
$27.21 - $41.0 $68,025 - $102,500
2,500 Added 75.76%
5,800 $9,000
Q1 2020

May 07, 2020

BUY
$19.54 - $38.85 $60,574 - $120,435
3,100 Added 1550.0%
3,300 $16,000
Q2 2019

Aug 09, 2019

BUY
$9.78 - $24.52 $1,955 - $4,904
200 New
200 $0
Q2 2018

Aug 10, 2018

SELL
$12.45 - $16.95 $12,450 - $16,950
-1,000 Closed
0 $0
Q1 2018

May 11, 2018

SELL
$8.1 - $19.5 $7,290 - $17,550
-900 Reduced 47.37%
1,000 $0
Q4 2017

Jan 17, 2018

BUY
$6.65 - $9.25 $5,985 - $8,325
900 Added 90.0%
1,900 $3,000
Q3 2017

Oct 17, 2017

BUY
$4.45 - $8.55 $4,450 - $8,550
1,000
1,000 $0

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.35B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.